As investors await the Supreme Court’s ruling today regarding Obamacare, they need to consider various scenarios and understand how the ETF market is likely to be affected by different outcomes, according to an article on ETF Database.

Looking at the possibilities broadly, pharmaceutical ETFs are likely to rise if the existing law is upheld; health care providers ETFs are going to be heavily affected by any ruling, and biotech ETFs will be least affected by the outcome—according to Michael Johnston, contributor to the ETFdb article.

The most beneficial outcome for the health care sector would be for the Supreme Court to side with the Obama administration, as it could potentially lead to as many as 30 million additional insured customers over the course of several years, the article said.

If the mandate is ruled as unconstitutional and is overturned, health care reform would be brought to a halt, and the entire plan would have to be started from the ground up. This would most likely reduce growth potential and overall attractiveness of a slew of ETFs, according to ETFdb.

If the court decides to compromise, and take parts of the mandate—what has been labeled as the worst case scenario—there would be no inflow of new insured Americans and tax and regulatory burdens would remain intact, the article reports, saying this would be neutral for ETFs.

Head over to ETFdb.com for the full story.